Drug Profile
Research programme: recombinant proteins - Yuhan Corporation
Alternative Names: YH 25348; YH 25723; YH-Bio1; YHbio1Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Yuhan
- Class Antifibrotics; Antihyperglycaemics; Hepatoprotectants; Recombinant fusion proteins; Recombinant proteins
- Mechanism of Action Fibroblast growth factor receptor agonists; Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Hepatic fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Hepatic-fibrosis in South Korea (Parenteral)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in South Korea (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in South Korea (Parenteral)